GlassScriptPhysician profile
Brett Scheidemantel
NPI 1952072688
$4,838.33
in general payments reported to CMS, 2019-2025
49 companies · $1,181 in 2025
The $1,181 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $178 · 2022: $1,444 · 2023: $1,149 · 2024: $886 · 2025: $1,181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,822 · Education: $394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,821.80 |
| Education | $393.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $468.48 | 2023-2024 | Xtandi |
| Procept Biorobotics Corporation | $397.45 | 2023-2025 | Aquabeam System, Aquabeam Robotic System |
| Janssen Biotech, INC. | $305.29 | 2023-2025 | Erleada, Akeega, Balversa |
| Lundbeck LLC | $304.53 | 2021-2022 | |
| Dendreon Pharmaceuticals LLC | $294.62 | 2023-2025 | Provenge |
| Sumitomo Pharma America, INC. | $267.93 | 2023-2025 | Orgovyx, Gemtesa |
| Vanda Pharmaceuticals INC. | $265.71 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $188.79 | 2022 | |
| Coloplast Corp | $153.47 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $129.83 | 2021-2022 | |
| Boston Scientific Corporation | $121.08 | 2023 | |
| Urogen Pharma, INC. | $117.57 | 2023-2025 | Jelmyto |
| Alkermes, INC. | $109.27 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $108.98 | 2022 | |
| Myriad Genetic Laboratories, INC. | $107.36 | 2023-2025 | Prolaris |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $94.47 | 2024 | Adstiladrin |
| Endo USA, INC. | $89.19 | 2024-2025 | Xiaflex |
| Tolmar, INC. | $77.94 | 2023-2025 | Eligard, Jatenzo |
| Janssen Pharmaceuticals, INC | $76.09 | 2022 | |
| Almatica Pharma LLC | $74.44 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $67.60 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $67.15 | 2024-2025 | Onglyza |
| Novartis Pharmaceuticals Corporation | $64.27 | 2025 | |
| Eisai INC. | $60.36 | 2021-2022 | |
| Accord Healthcare, INC. | $58.58 | 2023-2024 | |
| Neurocrine Biosciences, INC. | $54.19 | 2021-2022 | |
| Progenics Pharmaceuticals, INC. | $54.16 | 2023 | Pylarify |
| Olympus America INC. | $51.53 | 2024-2025 | Itind System |
| Neuronetics, INC. | $47.86 | 2022 | |
| Telix Pharmaceuticals | $45.02 | 2024 | Illuccix |
| Idorsia Pharmaceuticals US INC | $44.25 | 2022 | |
| Endo Pharmaceuticals INC. | $43.82 | 2023 | Aveed, Edex, Xiaflex |
| Janssen Scientific Affairs, LLC | $39.90 | 2024 | Akeega, Erleada |
| Bayer Healthcare Pharmaceuticals INC. | $37.15 | 2023-2025 | |
| Immunitybio, INC. | $35.48 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $33.86 | 2023 | Keytruda |
| Corium, LLC | $32.26 | 2022 | |
| Bausch Health US, LLC | $31.73 | 2022 | |
| Edap Technomed INC | $29.99 | 2025 | |
| Celltrion USA INC. | $24.15 | 2025 | Vegzelma |
| Organon LLC | $22.35 | 2025 | |
| Koelis INC. | $21.71 | 2023 | |
| Laborie Medical Technologies Corp. | $20.93 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
| Axonics, INC. | $19.96 | 2024 | Bulkamid |
| Photocure INC | $17.74 | 2024 | Cysview |
| Davol INC. | $16.96 | 2025 | Arista |
| Antares Pharma, INC. | $16.21 | 2025 | Xyosted |
| Alfasigma USA, INC. | $13.97 | 2022 | |
| Owp Pharmaceuticals, INC. | $12.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Scheidemantel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.